Your browser doesn't support javascript.
loading
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects.
Le, Tuyen T; Di Vincenzo, Joshua D; Teopiz, Kayla M; Lee, Yena; Cha, Danielle S; Lui, Leanna M W; Rodrigues, Nelson B; Ho, Roger C; Cao, Bing; Lin, Kangguang; Nasri, Flora; Gill, Hartej; Lipsitz, Orly; Subramaniapillai, Mehala; Mansur, Rodrigo B; Rosenblat, Joshua D; McIntyre, Roger S.
Affiliation
  • Le TT; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
  • Di Vincenzo JD; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Canadian Rapid Treat
  • Teopiz KM; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada.
  • Lee Y; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Cha DS; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
  • Lui LMW; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada.
  • Rodrigues NB; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Ho RC; Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore 117599, Singapore; Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore. Electronic address: pcmrhcm@nus.edu.sg.
  • Cao B; Key Laboratory of Cognition and Personality (SWU), Faculty of Psychology, Ministry of Education, Southwest University, Chongqing 400715, PR China.
  • Lin K; Department of Affective Disorder, the Affiliated Brain Hospital of Guangzhou Medical University, (Guangzhou Huiai Hospital), Guangzhou Medical University, Guangzhou, China; Laboratory of Emotion and Cognition, the Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital),
  • Nasri F; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada.
  • Gill H; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Lipsitz O; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Subramaniapillai M; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Mansur RB; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Rosenblat JD; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Psychiatry, Universit
  • McIntyre RS; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Canadian Rapid Treat
Psychiatry Res ; 306: 114231, 2021 12.
Article in En | MEDLINE | ID: mdl-34798487
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bipolar Disorder / Depressive Disorder, Major / Ketamine Type of study: Guideline / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Psychiatry Res Year: 2021 Document type: Article Affiliation country: Canada
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bipolar Disorder / Depressive Disorder, Major / Ketamine Type of study: Guideline / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Psychiatry Res Year: 2021 Document type: Article Affiliation country: Canada